Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Pfizer’s leukaemia drug gets opposing regulatory decisions on either side of the Atlantic

August 18, 2017
Medical Communications, Sales and Marketing Besponsa, Cancer, FDA, NICE, Pfizer, leukaemia, pharma, pharmaceutical

Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval …

News

NICE knocks back advanced kidney cancer drug duo

August 14, 2017
Sales and Marketing Cancer, Kidney cancer, NICE, medicine, pharma, pharmaceutical

NICE has dished out a double judgement turning down two drugs for advanced renal cell carcinoma, a form of kidney …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

August 11, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Merck, NICE, Parkinson's, biotech, diabetes, pharma, pharmaceutical, top ten

Another week, another busy week in pharma. The last seven days have seen some remarkable strides in the diabetes space, …

News

Bayer’s liver cancer drug availability spreads to UK with NICE approval

August 10, 2017
Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical

NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …

News

Merck scores expanded NICE recommendation in head, neck and oral cancer

August 8, 2017
Manufacturing and Production, Sales and Marketing Erbitux, Merck, NICE, biotech, cetuximah, drugs, life sciences, pharma, pharmaceuticals

Merck has announced its approval of NICE’s decision to expand its recommendation of Erbitux (cetuximab) to include its use as …

News
celgene_1_02

NICE greenlights Celgene pancreatic cancer drug as first-line combination treatment

August 4, 2017
Medical Communications, Sales and Marketing Cancer, Celgene, NICE, Pancreatic cancer, drugs, healthcare, life sciences, medicine, pharma, pharmaceuticals

Celgene is celebrating following NICE’s announcement that it had decided to recommend the use of nab-Paclitaxel, when used in combination …

News

Roche antibody becomes first of its kind authorised for blood cancer

July 26, 2017
Research and Development, Sales and Marketing CDF, Cancer, NICE, drugs, lymphoma, pharma, pharmaceutical Roche

NICE has announced its decision to make Roche’s Gazyvaro available via the Cancer Drugs Fund (CDF) in combination with chemotherapy …

News

Ipsen secures NICE approval for multi-targeting kidney cancer therapy

July 11, 2017
Manufacturing and Production, Sales and Marketing Cabometyx, Kidney cancer, NICE

Ipsen has announced that its therapy Cabometyx (cabozantinib) has been given approval by NICE for the treatment of advanced renal …

News

ABPI launches legal action to overturn £20m price cap

July 11, 2017
Manufacturing and Production, Medical Communications, Sales and Marketing ABPI, NHS England, NICE

When NICE announced in March that it would impose a £20 million per year cap on the price of drugs, …

News

NICE agrees approval deal for ultra-rare juvenile bone disease

July 5, 2017
Research and Development, Sales and Marketing Alexion, NICE, Strensiq

NICE has announced that it has decided to approve Alexion Pharma’s Strensiq (asfotase alfa) for the treatment of ultra-rare disease …

News
brexit_flag_0

Ministers move to clarify drug regulation Post-Brexit

July 4, 2017
Manufacturing and Production, Medical Communications EMA, Jeremy Hunt, MHRA, NHS, NICE

Jeremy Hunt, Health Secretary, and Greg Clark, Business Secretary, have made a bold move to suggest that the UK will …

News

NICE recommends AstraZeneca lung treatment

July 3, 2017
Sales and Marketing AstraZeneca, Daxas, NICE

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) it has emerged, …

News

Eli Lilly arthritis drug outperforms Humira and receives NICE backing

June 30, 2017
Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis

Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …

News

NICE U-turns to recommend Sanofi Gaucher disease drug

June 2, 2017
Medical Communications, Sales and Marketing Gaucher disease, NICE, Sanofi

It has been revealed that NICE has reached the decision to recommend Sanofi’s Cerdelga (eligustat) for use on the NHS …

News
scale-403585_960_720

Weight loss pill treatment rejected by NICE

May 8, 2017
Medical Communications, Sales and Marketing NICE, orexigen

NICE has announced, in an Appraisal Consultation Document, that it is not able to recommend Orexigen’s Mysimba as a weight …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026